OncoSil Medical (ASX:OSL) secured UK Conformity Assessed renewal certificates from the British Standards Institution (BSI) for its OncoSil pancreatic cancer treatment device, according to a Monday filing with the Australian Securities Exchange.
The certification allows the company to have continued access to the UK market without additional compliance burdens, the filing said.
The company is also expecting to receive Medical Device Regulation approval from BSI shortly, according to the filing.
Shares rose more than 8% in afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.